HK1248546A1 - Wt1抗原肽和免疫調節劑的組合 - Google Patents

Wt1抗原肽和免疫調節劑的組合

Info

Publication number
HK1248546A1
HK1248546A1 HK18108240.1A HK18108240A HK1248546A1 HK 1248546 A1 HK1248546 A1 HK 1248546A1 HK 18108240 A HK18108240 A HK 18108240A HK 1248546 A1 HK1248546 A1 HK 1248546A1
Authority
HK
Hong Kong
Prior art keywords
immunomodulator
combination
antigen peptide
antigen
peptide
Prior art date
Application number
HK18108240.1A
Other languages
English (en)
Inventor
Hideo Takasu
Megumi Nakamura
Masashi Goto
Natsuko Suginobe
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Int Inst Cancer Immunology Inc filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of HK1248546A1 publication Critical patent/HK1248546A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
HK18108240.1A 2015-05-20 2018-06-27 Wt1抗原肽和免疫調節劑的組合 HK1248546A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015103145 2015-05-20
PCT/JP2016/064923 WO2016186177A1 (ja) 2015-05-20 2016-05-19 Wt1抗原ペプチドおよび免疫調節剤の併用

Publications (1)

Publication Number Publication Date
HK1248546A1 true HK1248546A1 (zh) 2018-10-19

Family

ID=57320344

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18107308.2A HK1250213A1 (zh) 2015-05-20 2018-06-05 Wt1抗原肽和免疫調節劑的組合
HK18108240.1A HK1248546A1 (zh) 2015-05-20 2018-06-27 Wt1抗原肽和免疫調節劑的組合

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18107308.2A HK1250213A1 (zh) 2015-05-20 2018-06-05 Wt1抗原肽和免疫調節劑的組合

Country Status (7)

Country Link
US (1) US20180140691A1 (zh)
EP (1) EP3299028A4 (zh)
JP (4) JP6515182B2 (zh)
CN (1) CN107921106B (zh)
CA (1) CA2986367A1 (zh)
HK (2) HK1250213A1 (zh)
WO (1) WO2016186177A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
CN116327903A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
JP7209963B2 (ja) * 2016-11-30 2023-01-23 住友ファーマ株式会社 Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
SG11202001211TA (en) * 2017-08-28 2020-03-30 Bristol Myers Squibb Co Tim-3 antagonists for the treatment and diagnosis of cancers
CA3128468A1 (en) * 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
KR20210073540A (ko) * 2018-10-05 2021-06-18 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 양성 종양의 예방 또는 치료약
KR20220010712A (ko) * 2019-04-10 2022-01-26 에스엘에스지 리미티드 엘엘씨 Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
US20210030868A1 (en) * 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
US20230055555A1 (en) * 2019-12-10 2023-02-23 Sumitomo Pharma Co., Ltd. Method for preparing peptide emulsion formulation
CN115697374A (zh) * 2020-05-12 2023-02-03 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
EP4313046A1 (en) * 2021-03-31 2024-02-07 Celleron Therapeutics Limited Vaccine adjuvant

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578419A4 (en) * 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
KR20120054644A (ko) * 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
JP4921965B2 (ja) * 2003-03-27 2012-04-25 ランケナー インスティテュート フォー メディカル リサーチ 癌治療新規方式
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005004907A1 (en) * 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
MX2011005691A (es) * 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
NZ623807A (en) * 2010-04-13 2016-03-31 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
CN103157108B (zh) * 2011-12-13 2016-01-20 宁云山 免疫调节剂组合物及其药物组合物和应用
WO2013090293A1 (en) * 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN103830211A (zh) * 2012-11-27 2014-06-04 上海曼克尔瑞生物医药技术有限公司 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用
CN103961702B (zh) * 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
MY171854A (en) * 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
JP7253210B2 (ja) 2023-04-06
JPWO2016186177A1 (ja) 2018-04-12
JP2020075934A (ja) 2020-05-21
CA2986367A1 (en) 2016-11-24
US20180140691A1 (en) 2018-05-24
JP2022000454A (ja) 2022-01-04
JP2019135251A (ja) 2019-08-15
WO2016186177A1 (ja) 2016-11-24
JP6956967B2 (ja) 2021-11-02
EP3299028A1 (en) 2018-03-28
CN107921106A (zh) 2018-04-17
EP3299028A4 (en) 2019-02-27
HK1250213A1 (zh) 2018-12-07
JP6713160B2 (ja) 2020-06-24
CN107921106B (zh) 2023-09-08
JP6515182B2 (ja) 2019-05-15

Similar Documents

Publication Publication Date Title
HK1248546A1 (zh) Wt1抗原肽和免疫調節劑的組合
IL249032A0 (en) ras inhibitory peptides and their uses
IL284236A (en) Modifications and uses of conotoxin peptides
HK1251979A1 (zh) 肽組合物和使用方法
GB201621707D0 (en) Synthesis and use of amino lipids
IL259096A (en) Peptides and methods of treating endometriosis using the same
IL287985A (en) A peptide derived from koc1 and a component containing it
IL284792A (en) Peptide derivative - DEPDC1 and a component containing it
IL250215A0 (en) A peptide derived from cdca1 and a component containing it
IL251289B (en) New peptide derivatives and their use
PT3430390T (pt) Origem molecular da alergia
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL247448A0 (en) Peptides and methods of use
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
SG11201610918RA (en) Peptides and uses thereof
GB201401673D0 (en) Esculentin-2CHa peptide and analogues thereof
AU2015901160A0 (en) Immunomodulatory peptides and methods of use
GB201504211D0 (en) Use of peptides